The highly selective FGFR1-3 TKI pemigatinib (INCB054828) was firstly evaluated in a basket trial showing partial response in a CCA patient harbouring FGFR2-CCDC6 fusion [50]; no responses were reported in other FGFR aberrations. Here, FGFR2 is linked to cholangiocarcinoma.